559 related articles for article (PubMed ID: 27736664)
21. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
22. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
23. Genome Editing for the β-Hemoglobinopathies.
Porteus MH
Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
[TBL] [Abstract][Full Text] [Related]
24. Generating autologous hematopoietic cells from human-induced pluripotent stem cells through ectopic expression of transcription factors.
Hwang Y; Broxmeyer HE; Lee MR
Curr Opin Hematol; 2017 Jul; 24(4):283-288. PubMed ID: 28383341
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
26. Developmental progress of CRISPR/Cas9 and its therapeutic applications for HIV-1 infection.
Deng Q; Chen Z; Shi L; Lin H
Rev Med Virol; 2018 Sep; 28(5):e1998. PubMed ID: 30024073
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9-based gene-editing technology for sickle cell disease.
Ma L; Yang S; Peng Q; Zhang J; Zhang J
Gene; 2023 Jul; 874():147480. PubMed ID: 37182559
[TBL] [Abstract][Full Text] [Related]
28. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.
Xie F; Ye L; Chang JC; Beyer AI; Wang J; Muench MO; Kan YW
Genome Res; 2014 Sep; 24(9):1526-33. PubMed ID: 25096406
[TBL] [Abstract][Full Text] [Related]
29. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
30. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
[TBL] [Abstract][Full Text] [Related]
31. The Cas9 Hammer-and Sickle: A Challenge for Genome Editors.
Urnov FD
CRISPR J; 2021 Feb; 4(1):6-13. PubMed ID: 33616446
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for sickle cell disease.
The Lancet Haematology
Lancet Haematol; 2016 Oct; 3(10):e446. PubMed ID: 27692301
[No Abstract] [Full Text] [Related]
33. Gene Therapy for β-Hemoglobinopathies.
Cavazzana M; Antoniani C; Miccio A
Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
[TBL] [Abstract][Full Text] [Related]
34. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.
Alayoubi AM; Khawaji ZY; Mohammed MA; Mercier FE
Ann Hematol; 2024 Jun; 103(6):1805-1817. PubMed ID: 37736806
[TBL] [Abstract][Full Text] [Related]
35. [Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection].
Han Y; Li QW
Yi Chuan; 2016 Jan; 38(1):9-16. PubMed ID: 26787519
[TBL] [Abstract][Full Text] [Related]
36. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
Dannenmann B; Nasri M; Welte K; Skokowa J
Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
[TBL] [Abstract][Full Text] [Related]
38. Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction.
Li C; Ding L; Sun CW; Wu LC; Zhou D; Pawlik KM; Khodadadi-Jamayran A; Westin E; Goldman FD; Townes TM
Sci Rep; 2016 Jul; 6():30422. PubMed ID: 27460639
[TBL] [Abstract][Full Text] [Related]
39. Gene Therapy and Genome Editing.
Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
[TBL] [Abstract][Full Text] [Related]
40. Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.
Cai B; Sun S; Li Z; Zhang X; Ke Y; Yang J; Li X
Hum Genet; 2018 Sep; 137(9):679-688. PubMed ID: 30203114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]